Trial Profile

A Phase 1, human proof-of-concept clinical trial of BIO-205 in neuropathic pain

Status: Planning

Phase of Trial: Phase I

Latest Information Update: 14 Jan 2020

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs BIO 205 (Primary)
Indications Neuropathic pain
Focus Adverse reactions; Proof of concept
Sponsors BioIntervene

Most Recent Events

14 Jan 2020 New trial record
06 Jan 2020 According to an BioIntervene media release, the company has entered into a $30 million Series A financing. The proceeds of the financing will be used to advance BIO-205, through human proof-of-concept studies in neuropathic pain. BIO-205 is anticipated to enter Phase 1 clinical trials in the second half of 2020.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com